Clinical Scorecard: Prolonged Survival in a Patient with Alpha-Fetoprotein-Positive Hepatoid Adenocarcinoma of the Gallbladder: A Case Study and Review of Existing Literature

At a Glance

Key Highlights

• Hepatoid adenocarcinoma is a rare and aggressive variant of gallbladder carcinoma.
• The patient achieved 68 months of recurrence-free survival following radical resection and adjuvant TACE.
• Elevated serum AFP levels are a hallmark of this subtype, with a concentration of 1210.00 ng/mL at diagnosis.
• Genomic profiling revealed a TP53 mutation and EGFR amplification, indicating potential therapeutic targets.
• Histopathological analysis confirmed the diagnosis with strong positivity for AFP and other markers.

Guideline-Based Recommendations

Diagnosis

• Histopathological and immunohistochemical analyses are essential for diagnosis.

Management

• Radical resection followed by adjuvant transarterial chemoembolization (TACE) may improve outcomes.

Monitoring & Follow-up

• Serum AFP levels should be monitored postoperatively to assess treatment response.

Risks

• Hepatoid adenocarcinoma has a poor prognosis and is associated with aggressive disease.

Patient & Prescribing Data

66-year-old male with a history of hepatitis B virus infection.

Combination of surgical intervention and TACE led to normalization of serum AFP levels.

Clinical Best Practices

• Consider genomic profiling for targeted therapy options in aggressive cases.
• Regular follow-up and monitoring of serum AFP levels are crucial for early detection of recurrence.

Related Resources & Content

• Case Study and Literature Review